polycystic ovarian syndrome
Conditions
Interventions
Patients with polycystic ovary syndrome with insulin resistance:Nil
Pcos is not associated with insulin resistance:Nil
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1. Patients who intend to receive assisted reproductive technology for pregnancy; 2. The experimental group met the diagnostic criteria for polycystic ovary syndrome: the commonly used diagnostic criteria for polycystic ovary syndrome in the world include Rotterdam standard, ae-pcos standard and national institutes of health (NIH) standard.In this study, the diagnosis of polycystic ovary syndrome was referred to the "Chinese diagnosis and treatment guidelines for polycystic ovary syndrome" formulated by endocrinology group of obstetrics and gynecology branch of the Chinese medical association in 2018.The guidelines require the diagnosis of pcos to meet one, two and three of the following criteria, and exclude other conditions that may cause abnormal ovulation and hyperandrogenemia (including Cushing syndrome, androgen-secreting ovarian tumors, thyroid disease, hyperprolactiemia, etc.). (1) menorrhagia/amenorrhea/irregular uterine bleeding (menorrhagia is defined as the menstrual cycle longer than 35 days); (2) clinical or biochemical hyperandrogenemia: clinical hyperandrogenemia refers to hypertrophy with clinical manifestations of m-fg score >= 8, and biochemical hyperandrogenemia refers to serum free testosterone >= 0.034nmol/l. (3) polycystic ovarian changes observed under b-ultrasound: polycystic ovarian changes refer to 12 more follicles with 2-10mm diameter or unilateral ovarian volume >= 10ml in unilateral ovary. 3. Healthy volunteers usually have regular menstruation, and the menstrual cycle is between 28 and 35 days. No levonorgestrogesterone releasing intrauterine device or progesterone contraceptive is used to prevent pregnancy;(in our center, assisted reproductive technology is only used for "male factor" or "fallopian tube factor" to help pregnant patients) 4. Aged between 20 and 35; 5. 18 <= BMI <= 24.
Exclusion criteria
Exclusion criteria: 1. Excluding pregnancy and other causes of hyperandrogenemia (such as hyperprolactinemia and thyroid disease, congenital adrenocortical hyperplasia, Cushing's syndrome, androgen secreted tumors, 21-hydroxylase deficiency atypical adrenal hyperplasia, exogenous androgen use, etc., thyroid dysfunction. 2. Participants did not take management hormone drugs, insulin sensitizers or antibiotics for the first 3 months. Do not drink, smoke, take drugs that affect IR and inflammatory response (e. G. Estrogen, oral contraceptive, glucocorticoids, immunosuppressants, hypoglycemic drugs, hypotensive drugs, lipid-lowering drugs) and other inflammatory diseases (such as Crohn's disease) in the last 3 months. Ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, hypertension, benign or malignant hematological diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bacteria DNA; | — |
Countries
China
Contacts
Public ContactFangfang He
Xiangya Hospital, Central South University
Outcome results
None listed